先瑞達醫療-B(06669.HK)年度經調整溢利淨額4243.5萬元 同比增長22.1%
格隆匯3月25日丨先瑞達醫療-B(06669.HK)發佈公吿,產研的穩定利好狀態直接導致年度收益快速增長。截至2023年12月31日止年度,公司的收益約為人民幣473.8百萬元,同比增加約19.8%。公司的核心產品AcoArt Orchid &Dhalia及AcoArt Tulip & Litos成為公司收益的核心來源。年內經調整溢利淨額4243.5萬元,同比增長22.1%。
集團截至2023年12月31日止年度的研發成本約為人民幣190.1百萬元,較截至2022年12月31日止年度約人民幣183.8百萬元增加約3.4%。增加乃主要由於研發人員數目增加導致員工成本上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.